Super-Resolution Contrast-Enhanced Ultrasound Examination Down to the Microvasculature Enables Quantitative Analysis of Liver Lesions: First Results

Ulrich Kaiser(University of Applied Sciences Landshut), Ernst Michael Jung(University Hospital Regensburg), Ursula Vehling‐Kaiser(University of Applied Sciences Landshut), F. Jung(Brandenburg University of Technology Cottbus-Senftenberg), Fabian Kück(Universitätsmedizin Göttingen), Mia Gilanschah(University Hospital Regensburg)
Life
June 20, 2025
10.3390/life15070991
Cited by 4

Related Papers

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
|The Lancet|2013|1.5k
Vascular Endothelial Cell Biology: An Update
|International Journal of Molecular Sciences|2019|1.1k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
|The Lancet Oncology|2016|417
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
|The Lancet Oncology|2015|402